Aspirin, Vascular Disease and Cancer:
50 Years of Controversy and the Jury’s Still Out!
Volume 1 - Issue 5
Peter Elwood*
-
Author Information
Open or Close
- Department of Inst of Population Medicine, Cardiff University, UK
*Corresponding author:
Peter Elwood, Department of Inst of Population Medicine, Cardiff University, UK
Received: May 26, 2018; Published: June 11, 2018
DOI: 10.32474/OAJOM.2018.02.000126
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
The story of aspirin and vascular disease starts with John O
Brien, a haematologist in Portsmouth in the 1960s, who reported
that the ingestion of 150mg of aspirin substantially reduced the
aggregation of platelets [1]. On the basis of this finding, and the
assumption that the incidence of thrombosis would be reduced,
O’Brien persuaded the UK Medical Research Council in 1968 to
set up a randomised trial of aspirin [2].
Aspirin and Vascular Disease|
Aspirin and the Prevention of Cancer|
Aspirin and Bleeding|
Further Research|
Conclusion|
References|